Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France;Analyse coût/efficacité de l'association capécitabine- docétaxel versus docétaxel en monothérapie dans le cancer du sein métastatique ou localement avancé en France

Bulletin du Cancer

Volumn 92, Issue 9, 2005, Pages 809-816

  Priol, Gaël ^a   Maurel, Frédérique ^a   Le Pen, Claude ^a  

^a Aremis Consultants   (France)

Author keywords

Cost effectiveness ratio; Direct medical cost; Economic evaluation; Metastatic breast cancer

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; CAPECITABINE; DOCETAXEL; MORPHINE; PARACETAMOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; EVALUATION; FEMALE; FRANCE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MONEY; MONOTHERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; FRANCE; HOSPITAL COSTS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 26844518782     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al. Randomised phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367-72.
2. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93.
3. Final Clinical Study Report. Protocol SO14999C: an open label randomized phase III study of capécitabine in combination with docetaxel (Taxotere®) versus docetaxel monotherapy in patients with advanced and/or metastatic breast cancer. Research Report Number 1003795. 2001; (March 2).
4. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes CJ, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-23.
5. Lapeyre-Mestre M, Daly-Schveitzer N, Boussin G, Delande G. Évaluation coût-efficacité de la prise en charge du cancer du sein. Analyse comparative 1973-1985 dans un Centre de Lutte Contre le Cancer. Rev Epidemiol Sante Publique 1993; 41: 397-406.
6. Verma S, Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer 2003; 11: 728-34.
7. Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 2001; 9: 484-9.
8. Lindgren P, Jonsson B, Redaelli A, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 2002; 20: 101-8.
9. Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 2003; 8: 232-40.
10. Wait S, Schaffer P, Séradour B, Gulfendels C, Gairard B, Morin F, et al. The cost of breast cancer screening in France. J Radiol 2000; 81: 799-806.
11. Arveux P, Wait S, Schaffer P. Building a model to determine the cost-effectiveness of breast cancer screening in France. Eur J Cancer Care (Engl) 2003; 12: 143-53.
12. Lilliu H, Stevens D, Brun C, Morel J, Pen CL, Bonastre J, et al. Évaluation rétrospective du coût du cancer du sein dans un Centre de lutte contre le cancer. Bull Cancer 2002; 89: 635-42.
13. Launois RJ, Reboul-Marty JM, Bonneterre J. Évaluation médico-économique de la chimiothérapie de deuxième ligne dans le cancer du sein métastatique: comparaison du docétaxel, paclitaxel, et de la vinorelbine. Bull Cancer 1997; 84: 709-21.
14. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000; 11: 157-61.
15. Durand-Zaleski I, Roche B, Buyse M, Carlson R, O'Connell MJ, Rougier P, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1997; 89: 790-5.
16. Hillner BE, Smith TJ. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer. Semin Oncol 1996; 2(suppl. 5): 25-30.
17. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13: 2166-73.
18. Drummond M, O'Brien B, Stoddardt G, et al. Methods for the economic evaluation of health care programmes, Second Edition. Oxford: Oxford University Press, 1997.
19. Lilliu H, et al. Evaluation of treatment of costs with recombinant human granulocyte colony-stimulating factors in the mobilisation of stem cells. J Pharm Clin 1999; 18: 277-81.